NO20013146L - Middel for behandling av synscellefunksjonsforstyrrelse - Google Patents

Middel for behandling av synscellefunksjonsforstyrrelse

Info

Publication number
NO20013146L
NO20013146L NO20013146A NO20013146A NO20013146L NO 20013146 L NO20013146 L NO 20013146L NO 20013146 A NO20013146 A NO 20013146A NO 20013146 A NO20013146 A NO 20013146A NO 20013146 L NO20013146 L NO 20013146L
Authority
NO
Norway
Prior art keywords
treatment
cell dysfunction
visual cell
visual
dysfunction
Prior art date
Application number
NO20013146A
Other languages
English (en)
Other versions
NO20013146D0 (no
Inventor
Ryuji Ueno
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20013146D0 publication Critical patent/NO20013146D0/no
Publication of NO20013146L publication Critical patent/NO20013146L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20013146A 1998-12-24 2001-06-22 Middel for behandling av synscellefunksjonsforstyrrelse NO20013146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24
PCT/JP1999/007161 WO2000038703A1 (en) 1998-12-24 1999-12-20 Agent for treating visual cell function disorder

Publications (2)

Publication Number Publication Date
NO20013146D0 NO20013146D0 (no) 2001-06-22
NO20013146L true NO20013146L (no) 2001-08-20

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013146A NO20013146L (no) 1998-12-24 2001-06-22 Middel for behandling av synscellefunksjonsforstyrrelse

Country Status (13)

Country Link
EP (1) EP1140134A1 (no)
JP (1) JP2002542150A (no)
KR (1) KR20010099928A (no)
CN (1) CN1224420C (no)
AR (1) AR022017A1 (no)
AU (1) AU781049B2 (no)
BR (1) BR9917113A (no)
CA (1) CA2356382A1 (no)
MX (1) MXPA01006449A (no)
NO (1) NO20013146L (no)
NZ (1) NZ513111A (no)
TW (1) TW546145B (no)
WO (1) WO2000038703A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2003209297A1 (en) 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US7592330B2 (en) 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
EP3868407A4 (en) * 2018-10-15 2022-02-23 Osaka University MEDICATIONS FOR IMPROVING OR PREVENTING SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION AND METHODS OF SCREENING OF AN AGENT TO IMPROVE SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147936T1 (de) * 1990-08-23 1997-02-15 Univ New York Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
JP2002511868A (ja) * 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド 増殖性硝子体網膜症を治療するためのカルシウム遮断薬
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
EP1140134A1 (en) 2001-10-10
CN1352565A (zh) 2002-06-05
MXPA01006449A (es) 2002-04-24
WO2000038703A1 (en) 2000-07-06
CN1224420C (zh) 2005-10-26
NO20013146D0 (no) 2001-06-22
AR022017A1 (es) 2002-09-04
AU781049B2 (en) 2005-05-05
CA2356382A1 (en) 2000-07-06
KR20010099928A (ko) 2001-11-09
AU1690600A (en) 2000-07-31
TW546145B (en) 2003-08-11
JP2002542150A (ja) 2002-12-10
BR9917113A (pt) 2001-10-23
NZ513111A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
DE60020327D1 (de) Wasserbehandlungsvorrichtung
NO20012160D0 (no) Anordning for behandling av makulös degenerering
EE200200710A (et) Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69828821D1 (de) Wasserbehandlungsverfahren
NO952749L (no) Middel for vannbehandling
NO992237D0 (no) Vannbehandlingsprosess
DE69907917D1 (de) Selektive verfeinerung der maschen
DK0965566T3 (da) Fremgangsmåde til behandling af organisk spildevand
NO20010456D0 (no) Triazolopyridiner for behandling av trombose-problemer
NO20013146D0 (no) Middel for behandling av synscellefunksjonsforstyrrelser
ID16981A (id) Konsentrat-konsentrat mutiara yang encer
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
AU4774599A (en) Process for the treatment of waste water
NO20013596L (no) Slambehandling
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
AU3843600A (en) Bath equipped with water vibrator and therapeutic method using the same
NO20012616L (no) Middel til behandling av erektil malfunksjon
GB2332849B (en) Apparatus for the treatment of soil
ZA993450B (en) Decolourization of water.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application